Where are we with COVID-19 treatments, vaccines?
Celltrion, a leading biopharmaceutical company based in Incheon's Songdo, unveiled to the public its potential COVID-19 antibody treatment known as CT-P59, Dec. 22. / YonhapBy Lee Hyo-jin While both vaccines and treatments are needed in order to bring the COVID-19 pandemic under control, Korea seems to be showing faster progress in developing treatments compared to its vaccine development and procurement plans. The Ministry of Food and Drug Safety has approved a total of 29 clinical trials of potential COVID-19 treatments from domestic drug companies, among which 21 trials were underway as of Dec. 23. As several firms have recently announced promising results from their clinical trials, hopes are rising that the treatments may be commercialized for actual use soon, with a goal of release as early as January. Among them, Celltrion, a leading biopharmaceutical company based in Incheon's Songdo, unveiled to the public, Dec. 22, its treatment candidate known as CT-P59 (regdanvimab), a monoclonal antibody treatment, which it has been working on since May.On Nov. 25, it finished its Phase
